Effect of biotherapeutics on cyclosporin-induced Clostridium difficile infection in mice

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 4, 2010, Pages 832-838

  Kaur, Sukhminderjit ^a   Vaishnavi, Chetana ^a   Ray, Pallab ^a   Kochhar, Rakesh ^a   Prasad, Kaushal Kishor ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

BALB c mice; Biotherapeutics measures; Clostridium difficile associated disease; Immunosuppressive therapy

Indexed keywords

CYCLOSPORIN; EPIDERMAL GROWTH FACTOR; MYELOPEROXIDASE; PROBIOTIC AGENT; TOXIN; TOXIN A; TOXIN B; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; CELL DAMAGE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CONTROLLED STUDY; DISEASE MODEL; ENZYME ACTIVITY; EPITHELIUM; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; LACTOBACILLUS ACIDOPHILUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TYPHLITIS; WEIGHT CHANGE;

EID: 77950118229     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06135.x     Document Type: Article

References (49)

1. Hossain M, Crook TJ, Keoghane SR. Clostridium difficile in urology. Ann. R. Coll. Surg. Engl. 2008 90 : 36 9.
2. West M, Pirenne J, Chavers B et al. Clostridium difficile colitis after kidney and kidney-pancreas transplantation. Clin. Transplant. 1999 13 : 318 323.
3. Keven K, Basu A, Re L. Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation. Transpl. Infect. Dis. 2004 6 : 10 14.
4. Gellad ZF, Alexander BD, Liu JK et al. Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients. Transpl. Infect. Dis. 2007 17 : 1 5.
5. Sharma AK, Holder FE. Clostridium difficile diarrhea after use of tacrolimus following renal transplantation. Clin. Infect. Dis. 1998 27 : 1540 1541.
6. Valiquette L, Low DE, Pepin J, McGeer A. Clostridium difficile infection in hospitals: a brewing storm. CMAJ 2004 171 : 27 9.
7. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol. 2006 101 : 812 822.
8. McFarland LV. A review of the evidence of health claims for biotherapeutic agents. Microb. Ecol. Health Dis. 2000 12 : 65 76.
9. Wullet M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhea: a double-blind placebo-controlled trial. Scand. J. Infect. Dis. 2003 35 : 365 367.
10. Plummer S, Weaver MA, Harris JC, Dee P, Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int. Microbiol. 2004 7 : 59 62.
11. Dendukuri N, Costa V, McGregor M, Brophy JM. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systemic review. CMAJ 2006 173 : 167 170.
12. Procaccino F, Reinshagen M, Hoffmann P et al. Protective effect of epidermal growth factor in an experimental model of colitis in rats. Gastroenterology 1994 107 : 12 17.
13. Sinha A, Nightingale JMD, West KP, Berlango-Acosta J, Playford RJ. Epidermal growth factor enemas with mesalamine for mild to moderate left-sided ulcerative colitis or proctitis. N. Engl. J. Med. 2003 349 : 350 357.
14. Buret A, Oslon ME, Gall DJ, Hardin JA. Effects of orally administered epidermal growth factor on enteropathogenic Escherichia coli infection in rabbits. Infect. Immun. 1998 66 : 4917 4923.
15. Kaur S, Vaishnavi C, Prasad KK, Ray P, Kochhar R. Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice. Microbiol. Immunol. 2007 51 : 1209 1214.
16. Vaishnavi C, Kochhar R, Bhasin DK, Thapa BR, Singh K. Detection of Clostridium difficile toxin by an indigenously developed latex agglutination assay. Trop. Gastroenterol. 1999 20 : 33 5.
17. Bradely PP, Priebet DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with enzyme marker. J. Invest. Dermatol. 1982 78 : 206 209.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951 193 : 265 275.
19. Merrigan M, Sambol S, Johnson S, Gerding DN. Susceptibility of hamsters to human pathogenic Clostridium difficile strain B1 following clindamycin, ampicillin or ceftriaxone administration. Anaerobe 2003 9 : 91 5.
20. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J. Clostridium difficile-associated diarrhea and colitis. Infect. Control Hosp. Epidemiol. 1995 16 : 459 477.
21. Vaishnavi C, Bhasin D, Kochhar R, Singh K. Clostridium difficile toxin and faecal lactoferrin assays in adult patients. Microbes. Infect. 2000 2 : 1827 1830.
22. Vaishnavi C. Diagnostic approaches for antibiotic associated diarrhoea. Bull. PGI 2006 40 : 4 9.
23. Sohi S, Cohen RD. Management of refractory ulcerative colitis. Curr. Treat. Options Gastroenterol. 2006 9 : 234 245.
24. Arnold C, Von Sanden S, Theilacker C, Blum HE. Ulcerous colitis and infection with cytomegalovirus, herpes simplex virus and Clostridium difficile. Zeitschriff fur Gastroenterologie 2008 46 : 780 783.
25. Manian FA, Meyer L. CDAD rates (letter; comment). Infect. Control Hosp. Epidemiol. 1995 16 : 63 5.
26. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 2000 342 : 390 397.
27. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001 357 : 189 193.
28. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 2002 34 : 346 353.
29. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N. Engl. J. Med. 1994 330 : 257 262.
30. Pothoulakis C, Castagliuolo I, Leeman SE et al. Substance P receptor expression in intestinal epithelium in Clostridium difficile toxin A enteritis in rats. Am. J. Physiol. 1998 275 : G68 G75.
31. Rubin RH. Infectious disease complications of renal transplantation. Kidney Int. 1993 44 : 221.
32. Ginsburg PM, Thuluvath PJ. Diarrhea in liver transplant recipients: etiology and management. Liver Transpl. 2005 11 : 881 890.
33. Theunissen C, Knoop C, Nonhoff C et al. Clostridium difficile colitis in cystic fibrosis patients with and without lung transplantation. Transpl. Infect. Dis. 2008 10 : 240 244.
34. Milligan DW, Kelley JK. Pseudomembranous colitis in a leukemia unit: a report of five fatal cases. J. Clin. Pathol. 1979 32 : 1237 1243.
35. Chen FC, Woods R. Pseudomembranous panenteritis and septicaemia in a patient with ulcerative colitis. Aust. N. Z. J. Surg. 1996 66 : 565 567.
36. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect. Control Hosp. Epidemiol. 1999 20 : 43 50.
37. Naaber P, Smidt I, Stsepetova J, Brilene T, Annuk H, Mikelsaar M. Inhibition of Clostridium difficile strains by intestinal Lactobacillus species. J. Med. Microbiol. 2004 53 : 551 554.
38. Wagner RD, Pierson C, Warner T et al. Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice. Infect. Immun. 1997 65 : 4165 4172.
39. Schmitt SK, Corey R, Budev M et al. Safety of Lactobacillus acidophilus used in the treatment of Clostridium difficile colitis in transplant recipients. Am. J. Transplant. 2006 6 (Suppl. 2 963.
40. Pochapin M, Oltikar A, Pringle-Smith R, Schreiber C. A prospective, randomized placebo-controlled trial of Lactobacillus GG in combination with standard antibiotic for the treatment of Clostridium difficile infection. Am. J. Gastroenterol. 1998 93 : 1697 (Abstract).
41. Gauffin CP, Agüero G, Perdigon G. Adjuvant effects of Lactobacillus casei added to a renutrition diet in a malnourished mouse model. Biocell 2002 26 : 35 48.
42. Na X, Zhao D, Koon HW et al. Clostridium difficile toxin B activates the EGF receptor and the ERK/MAP kinase pathway in human colonocytes. Gastroenterology 2005 128 : 1002 1011.
43. Riegler M, Sedivy R, Sogukoglu T et al. Epidermal growth factor attenuates Clostridium difficile toxin A- and B-induced damage of human colonic mucosa. Am. J. Physiol. 1997 273 : G1014 1022.
44. Hardin JA, Buret A, Meddings JB, Gall DJ. Effect of epidermal growth factor on enterocyte brush-border surface area. Am. J. Physiol. 1993 264 : G312 G318.
45. Elliott SN, Wallace JL, McKnight W et al. Bacterial colonization and healing of gastric ulcers: the effects of epidermal growth factor. Am. J. Physiol. Gastrointest. Liver Physiol. 2000 278 : G105 G112.
46. Bass P, Luck MS. Effect of epidermal growth on experimental colitis in rat. J. Pharmacol. Exp. Ther. 1993 264 : 984 990.
47. Konturek SJ, Dembinski A, Warzecha Z, Brzozowski T, Gregory H. Role of epidermal growth factor in healing of chronic gastroduodenal ulcers in rats. Gastroenterology 1988 94 : 1300 1307.
48. Wilson KH, Sheagren JN, Freter R, Weatherbee L, Lyerly D. Gnotobiotic models for study of the microbial ecology of Clostridium difficile and Escherichia coli. J. Infect. Dis. 1986 153 : 547 551.
49. Naaber P, Mikelsaar RH, Salminen S, Mikelsaar M. Bacterial translocation, intestinal microflora and morphological changes of intestinal mucosa in experimental models of Clostridium difficile infection. J. Med. Microbiol. 1998 47 : 591 598.